Trialing

Providing equal access to clinical trials.

1️⃣ Search & find clinical trials
2️⃣ Explore nearby centres
3️⃣ Refer your patient in less than 24 hours

[Trialing @TrialingHealth]

🚀Trialing featured in @Oncoinfo_it !

Oncoinfo’s latest article highlights how Trialing is improving clinical trial accessibility in Italy and how oncologists can benefit from our app.

📰 Read the article to learn more: https://t.co/5OTdXrZqfp

#ClinicalTrials #Oncology #Innovation #Trialing

[Trialing @TrialingHealth]

🔍 Simplify clinical trial searches with Trialing:

✔️ Access detailed trial data

📍Locate trials across Europe

⏱Save time with quick, intuitive searches

📊Stay updated with real-time information

👩‍⚕️For Oncologists, By Experts: Trialing is designed with you in mind, ensuring a smooth, efficient experience to enhance patient care: https://t.co/vHivRwhLn5

#ClinicalTrials #Oncology #Innovation #Trialing

[Stephen V Liu, MD @StephenVLiu]

Randomized phase II study @TheLancetOncol shows that adding bevacizumab to pembrolizumab in previously treated nasopharygeal carcinoma improves RR (58.3% vs 12.5%) and significantly increased PFS to 13.8m from 1.6m: HR 0.25! #NPC

https://t.co/B9Kr0DrPuu

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024

https://t.co/CYQ74SrOUq

👉🏻The 2024 SABCS showcased the expanding role of liquid biopsy in advancing precision oncology for BC, with MRD emerging as a key area of interest. While evidence highlights its potential for early detection of recurrence and risk stratification, validating its clinical utility and impact on patient outcomes remains a priority.
@OncoAlert #OncoAlertAF

[Yakup Ergün @dr_yakupergun]

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met–overexpressing, EGFR-mutated locally advanced/metastatic NSCLC after progression on prior osimertinib

ORR➡️50%
G3-4 Pulmonary embolism➡️8%!
https://t.co/JFbqKKuJMQ

[Trialing @TrialingHealth]

New Insights on National Cancer Control Plans (NCCPs) 📊

A recent policy review in The Lancet Oncology highlights significant gaps and progress in national cancer control strategies globally. 

🔑 Key Findings:

🔬 While 96% of NCCPs define cancer control goals, only 1% reference scientific evidence for all strategies and interventions.

🧪 81% of NCCPs include strategies for cancer research, and 45% have strategies focused on clinical trials. 38% had strategies related to the development of a national research agenda.

🌍 Though 40% of NCCPs mention health equity, only 18% of plans included strategies to address social determinants of health, such as employment, insurance, education, transportation, housing, and environmental changes. Only 32% mentioned vulnerable populations.

Read more here: https://t.co/YsZmr8DEX2

#CancerControl #CancerResearch #ClinicalTrials #HealthEquity #Trialing

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

🚨Major breakthrough from #PressRelease

The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀
https://t.co/QYBzGiKrgJ

[Toni Choueiri, MD @DrChoueiri]

END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @A@ASCO @ProfCUBlankNKI

https://t.co/3ndFElEAA8

[Trialing @TrialingHealth]

As 2024 ends, we highlight 3 key FDA & EMA oncology approvals:

1️⃣ Front-line Immunotherapy in Urothelial Carcinoma

- Nivolumab + chemotherapy: Improved long-term survival.
- Pembrolizumab + enfortumab vedotin: Superior progression-free & overall survival, now recommended in ESMO guidelines.

2️⃣ Tarlatamab for Relapsed SCLC

DLL3-targeting bispecific antibody shows durable responses and promising survival in pretreated patients.

3️⃣ Amivantamab in EGFR-Mutated NSCLC

For EGFR exon 19 or L858R mutations after EGFR inhibitors, showing improved progression-free survival.

💡 Full info here: https://t.co/td97wTTZZG

👉 Explore more on the Trialing App: https://t.co/vHivRwhLn5

#Oncology #ClinicalTrials #CancerCare #Trialing

[Oncology Brothers @OncBrothers]

2024 approvals: Summary of 6 new drugs/indications in GI Malignancies by @US_FDA

1. #LiposomalIrinotecan
2. #Adagrasib
3. #Zolbetuximab
4. #Zanidatamab
5. #Zenocutuzumab
6. #Encorafenib

#gism #OncTwitter #MedTwitter #PancChat

[Toni Choueiri, MD @DrChoueiri]

And NOW, TOP 5 PROSTATE CANCER trials of 2024!

1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile.
⛹🏼‍♂️A new player for doublets in mHSPC!

#ESMO24 Dr. Fred Saad @Silke_Gillessen @neerajaiims @umangtalking @DrRanaMcKay @JCO_ASCO

https://t.co/pdSS2DZJcX

[Stephanie Saw @stephanieplsaw]

Inspired by my good friend and slide master @JordiRemon - sharing these updated summary slides for 1L and post-progression treatment options for advanced stage EGFR-mutated NSCLC. Might be outdated soon but hopefully not before 2025 😬 @OncoAlert

[Trialing @TrialingHealth]

✨🎄 Season’s Greetings from all of us at Trialing 🎄✨

The Trialing team wishes you a joyful festive season and a successful 2025.

We hope that 2025 brings new and accessible cancer clinical trials, advancing innovative treatments and ensuring that no patient is left behind worldwide.

#ClinicalTrials #Trialing #Oncology

[Trialing @TrialingHealth]

A través de #TrialingApp puedes explorar los más de 300 ensayos clínicos disponibles en Europa para cáncer de pulmón👇

🔗 Link a la app:https://t.co/m7a7AaesjE

🗂️ Ruta: Tumores torácicos &gt; Cáncer de pulmón

#LungCancer #ClinicalTrials #Trialing

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

¿Qué ensayos clínicos hay disponibles?
#LCSM 🫁

[Trialing @TrialingHealth]

[ITALIANO]
✨ Grandangolo 2024 inizia oggi! 🇮🇹

Trialing sarà presente per connettersi con i professionisti dell'oncologia e mostrare come la nostra app semplifica la ricerca di clinical trial per gli oncologi.

📅 19-20 Dicembre
📍 Genova, Italia

Ci vediamo lì! 🤝

[ENGLISH]
✨ Grandangolo 2024 starts today! 🇮🇹

Trialing will be there to connect with oncology professionals and showcase how our app simplifies clinical trial searches for oncologists.

📅 19-20 December
📍 Genoa, Italy

See you there! 🤝

#Grandangolo #accmed #Oncologia #Oncology #ClinicalTrials #StudiClinici #Trialing

[Trialing @TrialingHealth]

📊 Adolescents & young adults (15–39) face an increasing cancer burden: 1.3M cases & 377K deaths in 2022. By 2050, cases will double in low human development index regions. 

Read more here: https://t.co/qsJYX32LEu

Bridging gaps in care and access to clinical trials is vital. AYAs deserve equitable cancer care. 🌍

#Oncology #ClinicalTrials #AYA #Trialing

[Trialing @TrialingHealth]

[ITALIANO]

🚀 La prossima settimana saremo al Grandangolo 2024 in Italia 🇮🇹!

Siamo entusiasti di entrare in contatto con i professionisti dell'oncologia e di mostrare come Trialing semplifica la ricerca dei trial clinici e supporta gli oncologi nel processo di riferimento dei pazienti.

📅 19-20 dicembre

📍 Genova, Italia

Connettiamoci! 🤝

#Grandangolo #accmed #Oncologia #Oncology #ClinicalTrials #StudiClinici #Trialing

[ENGLISH]

🚀 Next week, we will be at Grandangolo 2024 in Italy 🇮🇹!

We’re excited to connect with oncology professionals and demonstrate how Trialing simplifies searching for clinical trials and supports oncologists in the patient referral process.

📅 19-20 December

📍 Genoa, Italy

Let’s connect! 🤝

#Grandangolo #accmed #Oncologia #Oncology #ClinicalTrials #StudiClinici #Trialing

[Trialing @TrialingHealth]

🚀 AI is transforming cancer detection by analysing medical records, paving the way for personalised care and earlier interventions.

A recent article in The Lancet Oncology highlights key advancements in AI-powered data mining:

✅ AI models analyse population-wide health records, accounting for patient heterogeneity.

✅ Enhanced predictive power across diverse populations.

✅ AI maps malignant phenotypes to a risk continuum, improving screening methods.

⚠️ Challenges remain: data biases, ethics, and infrastructure hurdles.

#AI #Oncology #CancerDetection #Innovation #Healthcare

[The Lancet Oncology @TheLancetOncol]

New in the December issue:

Review: Artificial intelligence-aided data mining of medical records for #cancer detection and screening
#AI #data #medical records https://t.co/Q698hTn94R

[Trialing @TrialingHealth]

At Trialing, we’re proud to simplify oncology care by streamlining the clinical trial search process. Oncologists' feedback inspires us to keep innovating:

🗣️ “Trialing helps me find the best clinical trial for each patient in seconds, making referrals simple and reliable.”

🗣️ “The updates are constant, and the team is always available to assist with specific trial queries.”

💬 Got suggestions or feedback? Reach us easily via WhatsApp at [phone].

We’re here to support oncologists in their mission to deliver exceptional patient care.

#Oncology #ClinicalTrials #Innovation #CancerCare

[Trialing @TrialingHealth]

🚨 Oncology Regulatory News

🇺🇸 Zanidatamab receives FDA accelerated approval for HER2+ biliary tract cancer after progression (41% ORR in HERIZON-BTC-01).

🇪🇸 Sacituzumab Govitecan granted CIPM approval for RH+/HER2- metastatic breast cancer in Spain.

More info: https://t.co/5ZKNUdS6wq

🌟 Follow us for more updates in oncology advancements!

#Oncology #ClinicalTrials #FDAApproval #BiliaryTractCancer #BreastCancer #Trialing